Pharmacokinetics, Forensic Medicine, Anesthesiology Other
Conditions
Interventions
300 healthy volunteers will be genetically screened for single nucleotide polymorphisms (SNP) in the Cytochrome P450 2C9 (CYP2C9) gene. The three alleles identified for this study will be
1. Wild Typ
11 12 13 22 23 33. Each group consists of about 5 people, although there may be some differences due to allelic frequencies. We will not study more than 30 volunteers. If more than 5 persons in a spec
Sponsors
Inselspital (Switzerland)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers 2. 18-65 years old
Exclusion criteria
Exclusion criteria: 1. Refusal to participate 2. Does not speak or read German 3. Ongoing smoking status (<3 months since quitting) 4. Extreme nutritive status (BMI outside 16-35) 5. American Society of Anesthesiologists Status Class III and above 6. Suspected coronary heart disease 7. Major heart rhythm disturbances 8. Liver enzymes P450 altering medication 9. Any treated or suspected psychiatric diseases at any time during lifetime. This includes, but is not restricted to schizophrenic disorders, depression, use of heroin, cocaine, LSD, and ongoing use of THC (<1 month since quitting). 10. Pregnant, women will be tested by urine Human Chorionic Gonadotropin (HCG)-stick
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood levels of THC and degradation products, assessed by blood sampling at baseline, and 1, 2, 5, 10, 15, 20, 30, 45, 60, 90, 180, 300 Minutes and 24h, 48h after THC injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Vitals 2. Side effects 3. Well being, assessed by questionnaires filled out at regular intervals as well by Visual Analogue Scale (VAS) 4. Pupillometry will obtained in a subgroup using standardised techniques | — |
Countries
Switzerland
Outcome results
None listed